Kezar Life Sciences, INC Form 4 insider transactions

Courtney reports changes in beneficial ownership of Kezar Life Sciences stock options following a merger.

Mark C. Schiller's Form 4 details the cancellation and conversion of his stock options following Kezar Life Sciences' merger with Aurinia Pharma.

Micki Klearman, a Director at Kezar Life Sciences, Inc., reported transactions related to stock options on May 11, 2026, following a merger.

Christopher J. Kirk, CEO of Kezar Life Sciences, reported changes in beneficial ownership following the company's merger with Aurinia Pharma U.S., Inc.

Kezar Life Sciences, Inc. announced the completion of its merger with Aurinia Pharma U.S., Inc., resulting in the cancellation of certain stock options and the issuance of cash and contingent value rights.

Kezar Life Sciences reports changes in beneficial ownership for Director Graham K. Cooper following the company's merger completion on May 11, 2026.

Elizabeth Garner, a Director at Kezar Life Sciences, Inc., reported transactions related to stock options on May 11, 2026, following a merger.

Kezar Life Sciences, Inc. announces the completion of its merger with Aurinia Pharma U.S., Inc., resulting in the cancellation of stock options.

Kezar Life Sciences, Inc. announced the completion of its merger with Aurinia Pharma U.S., Inc., resulting in the cancellation of certain executive stock options.

John Fowler, a Director at Kezar Life Sciences, Inc., reported transactions related to stock options and common stock following a merger.

Kezar Life Sciences, Inc. announced the completion of its merger with Aurinia Pharma U.S., Inc., resulting in the cancellation of stock options.

Kezar Life Sciences' SVP, Corporate Controller, Pichi Luo Chiang, sold 264 shares of common stock at $4.28 per share to satisfy tax withholding obligations related to restricted stock unit vesting.

Kezar Life Sciences' Chief Operating Officer, Mark C. Schiller, sold 561 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Kezar Life Sciences, Inc.'s Chief Development Officer, To Zung Phuong, was granted 7,000 employee stock options with an exercise price of $4.40, vesting monthly over four years starting July 1, 2025.

Kezar Life Sciences, Inc. Director Micki Klearman was granted 5,000 stock options with an exercise price of $4.46 per share, vesting in June 2026.

Kezar Life Sciences, Inc. disclosed that Director Michael Kauffman was granted 5,000 stock options with an exercise price of $4.46, vesting in June 2026.

Kezar Life Sciences, Inc. Director Courtney Wallace was granted 5,000 stock options with an exercise price of $4.46, vesting fully in June 2026.

Kezar Life Sciences, Inc. Director Elizabeth Garner was granted 5,000 stock options with an exercise price of $4.46, vesting fully on June 18, 2026, as part of a pre-arranged Rule 10b5-1 plan.

Kezar Life Sciences, Inc. Director Graham K. Cooper was granted 5,000 stock options with an exercise price of $4.46 per share, vesting in June 2026.

Kezar Life Sciences, Inc. Director Franklin M. Berger was granted 5,000 stock options with an exercise price of $4.46, vesting fully in June 2026.

John Franklin Fowler, a Director at Kezar Life Sciences, Inc., was granted 5,000 stock options with an exercise price of $4.46, vesting fully in one year.

Mark C. Schiller, Chief Legal Officer of Kezar Life Sciences, reports the acquisition of stock options following the achievement of performance criteria.

Chief Financial Officer of Kezar Life Sciences, Marc Belsky, reports the grant of a stock option for 12,000 shares, vesting upon achievement of performance criteria and continued service.

Marc Belsky, CFO of Kezar Life Sciences, gains rights to purchase 7,200 shares of common stock following achievement of performance criteria.

Mark C. Schiller, Chief Legal Officer of Kezar Life Sciences, gains rights to purchase 7,200 shares of common stock following achievement of performance criteria.

John Franklin Fowler, a director at Kezar Life Sciences, acquired 5,000 stock options on February 14, 2025, exercisable for common stock.

Mark C. Schiller, Chief Legal Officer of Kezar Life Sciences, acquired 24,500 employee stock options on January 9, 2025.

Marc Belsky, CFO of Kezar Life Sciences, reports the acquisition of stock options in a recent SEC Form 4 filing.

Kezar Life Sciences CEO, Christopher J. Kirk, reports the acquisition of 120,000 employee stock options.

Mark C. Schiller, Chief Legal Officer of Kezar Life Sciences, sold 6,688 shares of common stock to cover statutory tax withholding obligations related to vesting restricted stock units.